Advertisement

Bullous Diseases: Old Blisters with New Therapeutic Targets

  • Kyle T. AmberEmail author
  • Rüdiger Eming
  • Michael Hertl
Chapter

Abstract

Immunobullous diseases are rare but potentially life threatening diseases that often require aggressive immunosuppression. While traditionally this has been in the form of broad immunosuppression with small-molecule drugs such as corticosteroids, newer therapies have arisen, targeting more specific pathways in the immunopathogenesis of the disease. We discuss the use of immunoadsorption, intravenous immunoglobulin, and rituximab in different bullous diseases, as well as the underlying mechanism behind these drugs.

Keywords

Systemic Lupus Erythematosus Aseptic Meningitis Bullous Pemphigoid Mucous Membrane Pemphigoid Epidermolysis Bullosa Acquisita 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris–incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Beutner EH, Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med. 1964;117:505–10.PubMedGoogle Scholar
  3. 3.
    Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest. 1992;90:919–26.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest. 1998;102:775–82.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Amagai M, Karpati S, Klaus-Kovtun V, Udey MC, Stanley JR. Extracellular domain of pemphigus vulgaris antigen (desmoglein 3) mediates weak homophilic adhesion. J Invest Dermatol. 1994;103:609–15.PubMedGoogle Scholar
  6. 6.
    Di Zenzo G, Di Lullo G, Corti D, et al. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. J Clin Invest. 2012;122:3781–90.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997;159:2010–7.PubMedGoogle Scholar
  8. 8.
    Muller R, Svoboda V, Wenzel E, Muller HH, Hertl M. IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris. Exp Dermatol. 2008;17:35–43.PubMedGoogle Scholar
  9. 9.
    Amber KT, Staropoli P, Shiman MI, Elgart GW, Hertl M. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol. 2013;22:699–704.PubMedGoogle Scholar
  10. 10.
    Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006;116:1159–66.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Nagel A, Lang A, Engel D, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol. 2010;134:320–30.PubMedGoogle Scholar
  12. 12.
    Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges. 2011;9:927–47.PubMedGoogle Scholar
  13. 13.
    Hertl M, Jedlickova H, Karpati S et al. Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2014. doi:  10.1111/jdv.12772. [Epub ahead of print].
  14. 14.
    Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity. 2006;39:609–16.PubMedGoogle Scholar
  15. 15.
    Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res. 2010;302:241–53.PubMedGoogle Scholar
  16. 16.
    Schmidt E, Klinker E, Opitz A, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol. 2003;148:1222–9.PubMedGoogle Scholar
  17. 17.
    Luftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol. 2003;149:598–605.PubMedGoogle Scholar
  18. 18.
    Eming R, Rech J, Barth S, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology. 2006;212:177–87.PubMedGoogle Scholar
  19. 19.
    Gunther C, Laske J, Frind A, Julius U, Pfeiffer C. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber. J Dtsch Dermatol Ges. 2008;6:661–3.PubMedGoogle Scholar
  20. 20.
    Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166:154–60.PubMedGoogle Scholar
  21. 21.
    Behzad M, Mobs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012;166:844–52.PubMedGoogle Scholar
  22. 22.
    Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012;10:727–32.PubMedGoogle Scholar
  23. 23.
    Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol. 2008;58:796–801.PubMedGoogle Scholar
  24. 24.
    Herzog S, Schmidt E, Goebeler M, Brocker EB, Zillikens D. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol. 2004;84:48–52.PubMedGoogle Scholar
  25. 25.
    Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol. 2013;93:346–9.PubMedGoogle Scholar
  26. 26.
    Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol. 2002;138:1158–62.PubMedGoogle Scholar
  27. 27.
    Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol. 2008;144:1621–4.PubMedGoogle Scholar
  28. 28.
    Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60:595–603.PubMedGoogle Scholar
  29. 29.
    Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120:214–22.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Rouziere AS, Kneitz C, Palanichamy A, Dorner T, Tony HP. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther. 2005;7:R714–24.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613–20.PubMedGoogle Scholar
  32. 32.
    Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–52.PubMedGoogle Scholar
  33. 33.
    Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128:2850–8.PubMedGoogle Scholar
  34. 34.
    Muller R, Hunzelmann N, Baur V, et al. Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. Dermatol Res Pract. 2010;2010:321950.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Reguiai Z, Tabary T, Maizieres M, Bernard P. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol. 2012;67:623–9.PubMedGoogle Scholar
  36. 36.
    Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128:2859–69.PubMedGoogle Scholar
  37. 37.
    Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5:175ra130.Google Scholar
  38. 38.
    Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48:2146–54.PubMedGoogle Scholar
  39. 39.
    Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis. 2008;67:1011–6.PubMedGoogle Scholar
  40. 40.
    Teng YK, Wheater G, Hogan VE, et al. Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. Arthritis Res Ther. 2012;14:R57.PubMedCentralPubMedGoogle Scholar
  41. 41.
    Ferraro AJ, Drayson MT, Savage CO, MacLennan IC. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol. 2008;38:292–8.PubMedGoogle Scholar
  42. 42.
    Nagel A, Podstawa E, Eickmann M, Muller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol. 2009;129:2202–10.PubMedGoogle Scholar
  43. 43.
    Hall 3rd RP, Streilein RD, Hannah DL, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133:2786–8.PubMedGoogle Scholar
  44. 44.
    Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203:743–53.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670–3.PubMedGoogle Scholar
  46. 46.
    Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823–37.PubMedGoogle Scholar
  47. 47.
    Golay J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica. 2003;88:1002–12.PubMedGoogle Scholar
  48. 48.
    Fischer L, Penack O, Gentilini C, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol. 2006;34:753–9.PubMedGoogle Scholar
  49. 49.
    Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells–enhancement by therapeutic antibodies. PLoS One. 2007;2:e326.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Berdeja JG, Hess A, Lucas DM, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res. 2007;13:2392–9.PubMedGoogle Scholar
  51. 51.
    Lee CS, Ashton-Key M, Cogliatti S, et al. Expression of inhibitory Fc receptor (Fc?RIIB) is a marker of poor response to rituximab monotherapy in follicular lymphoma. Lancet. 2013;381:S63.Google Scholar
  52. 52.
    Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–6.PubMedGoogle Scholar
  53. 53.
    Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232–9.PubMedGoogle Scholar
  54. 54.
    Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45.PubMedGoogle Scholar
  55. 55.
    Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001;98:2771–7.PubMedGoogle Scholar
  56. 56.
    Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171:1581–7.PubMedGoogle Scholar
  57. 57.
    Kennedy AD, Solga MD, Schuman TA, et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood. 2003;101:1071–9.PubMedGoogle Scholar
  58. 58.
    Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101:1045–52.PubMedGoogle Scholar
  59. 59.
    Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738–43.PubMedGoogle Scholar
  60. 60.
    Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900–8.PubMedGoogle Scholar
  61. 61.
    Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001;24:263–71.Google Scholar
  62. 62.
    Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica. 2006;91:176–83.PubMedGoogle Scholar
  63. 63.
    Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM. 2008;101:737–40.PubMedGoogle Scholar
  64. 64.
    Lessey E, Li N, Diaz L, Liu Z. Complement and cutaneous autoimmune blistering diseases. Immunol Res. 2008;41:223–32.PubMedGoogle Scholar
  65. 65.
    Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644–52.PubMedGoogle Scholar
  66. 66.
    Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003;63:5480–9.PubMedGoogle Scholar
  67. 67.
    Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20:444–9.PubMedCentralPubMedGoogle Scholar
  68. 68.
    Tsunoda K, Ota T, Suzuki H, et al. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur J Immunol. 2002;32:627–33.PubMedGoogle Scholar
  69. 69.
    Ujiie H, Shibaki A, Nishie W, et al. Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model. Clin Immunol. 2012;142:167–75.PubMedGoogle Scholar
  70. 70.
    Sitaru AG, Sesarman A, Mihai S, et al. T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita. J Immunol. 2010;184:1596–603.PubMedGoogle Scholar
  71. 71.
    Bortnick A, Allman D. What is and what should always have been: long-lived plasma cells induced by T cell-independent antigens. J Immunol. 2013;190:5913–8.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Xu W, Banchereau J. The antigen presenting cells instruct plasma cell differentiation. Front Immunol. 2014;4:504.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Leshem Y A, David M, Hodak E, et al. A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab. Arch Dermatol Res. 2014;306(1):67–74.Google Scholar
  74. 74.
    Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123:66–73.PubMedGoogle Scholar
  75. 75.
    Toubi E, Kessel A, Slobodin G, et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818–20.PubMedCentralPubMedGoogle Scholar
  76. 76.
    Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924–30.PubMedGoogle Scholar
  77. 77.
    Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112:1147–50.PubMedGoogle Scholar
  78. 78.
    Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62–74.PubMedGoogle Scholar
  79. 79.
    Feuchtenberger M, Muller S, Roll P, et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J. 2008;2:81–8.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52:501–13.PubMedGoogle Scholar
  81. 81.
    Wilk E, Witte T, Marquardt N, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009;60:3563–71.PubMedGoogle Scholar
  82. 82.
    Lunardon L, Payne AS. Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus. J Allergy Clin Immunol. 2012;130:800–3.PubMedCentralPubMedGoogle Scholar
  83. 83.
    Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol. 2009;132:334–41.PubMedGoogle Scholar
  84. 84.
    Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–7.PubMedGoogle Scholar
  85. 85.
    Dall’Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64:4664–9.PubMedGoogle Scholar
  86. 86.
    Gamonet C, Ferrand C, Colliou N, et al. Lack of expression of an alternative CD20 transcript variant in circulating B cells from patients with pemphigus. Exp Dermatol. 2014;23:66–7.PubMedGoogle Scholar
  87. 87.
    Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11:R123.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol. 2014. doi:  10.1111/jdv.12678. [Epub ahead of print].
  89. 89.
    Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68:404–11.PubMedGoogle Scholar
  90. 90.
    Balighi K, Daneshpazhooh M, Khezri S, Mahdavi-nia M, Hajiseyed-javadi M, Chams-Davatchi C. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52:862–7.PubMedGoogle Scholar
  91. 91.
    Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–6.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pita O. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67:617–22.PubMedGoogle Scholar
  93. 93.
    Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.PubMedGoogle Scholar
  94. 94.
    Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. 2011;7:529–41.PubMedGoogle Scholar
  95. 95.
    Zakka LR, Shetty SS, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb). 2012;2:17.Google Scholar
  96. 96.
    Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high and low dose rituximab treatments in pemphigus patients: a randomized comparative observer blinded study. Br J Dermatol. 2014;170(6):1341–9.Google Scholar
  97. 97.
    Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol. 2003;49:1059–62.PubMedGoogle Scholar
  98. 98.
    Leger S, Picard D, Ingen-Housz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148:1165–72.PubMedGoogle Scholar
  99. 99.
    Vezzoli P, Berti E, Marzano AV. Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus. Expert Rev Clin Immunol. 2008;4:351–63.PubMedGoogle Scholar
  100. 100.
    Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43:619–26.PubMedGoogle Scholar
  101. 101.
    Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol. 2003;2:564–7.PubMedGoogle Scholar
  102. 102.
    Shetty S, Ahmed AR. Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature. J Drugs Dermatol. 2013;12:672–7.PubMedGoogle Scholar
  103. 103.
    Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147:843–9.PubMedGoogle Scholar
  104. 104.
    Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol. 2013;69:310–1.PubMedGoogle Scholar
  105. 105.
    Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol. 2013;68:499–506.PubMedGoogle Scholar
  106. 106.
    Niedermeier A, Eming R, Pfutze M, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007;143:192–8.PubMedGoogle Scholar
  107. 107.
    McKinley SK, Huang JT, Tan J, Kroshinsky D, Gellis S. A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy. Pediatr Dermatol. 2014;31(2):241–4.Google Scholar
  108. 108.
    Cavailhes A, Balme B, Gilbert D, Skowron F. Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita. Ann Dermatol Venereol. 2009;136:795–9.PubMedGoogle Scholar
  109. 109.
    Schmidt E, Benoit S, Brocker EB, Zillikens D, Goebeler M. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol. 2006;142:147–50.PubMedGoogle Scholar
  110. 110.
    Kim JH, Lee SE, Kim SC. Successful treatment of epidermolysis bullosa acquisita with rituximab therapy. J Dermatol. 2012;39:477–9.PubMedGoogle Scholar
  111. 111.
    Kubisch I, Diessenbacher P, Schmidt E, Gollnick H, Leverkus M. Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. Am J Clin Dermatol. 2010;11:289–93.PubMedGoogle Scholar
  112. 112.
    Saha M, Cutler T, Bhogal B, Black MM, Groves RW. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol. 2009;34:e979–80.PubMedGoogle Scholar
  113. 113.
    Sadler E, Schafleitner B, Lanschuetzer C, et al. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol. 2007;157:417–9.PubMedGoogle Scholar
  114. 114.
    Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007;156:194–6.PubMedGoogle Scholar
  115. 115.
    Ludwig RJ. Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol. 2013;2013:812029.PubMedCentralPubMedGoogle Scholar
  116. 116.
    Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.PubMedGoogle Scholar
  117. 117.
    Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130:2041–8.PubMedGoogle Scholar
  118. 118.
    Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117:861–9.PubMedGoogle Scholar
  119. 119.
    Ventura F, Rocha J, Fernandes JC, Machado A, Brito C. Recalcitrant pemphigus vulgaris: aseptic meningitis associated with intravenous immunoglobulin therapy and successful treatment with rituximab. Int J Dermatol. 2013;52:501–2.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Dermatology and Cutaneous SurgeryUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Department of Dermatology and AllergologyPhilipps-UniversityMarburgGermany

Personalised recommendations